Related Experiment Video
Updated: Jul 28, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Antiplatelet and anticoagulant drugs in coronary vascular disease
1Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN.
Insights
Platelets and coagulation are key in heart attack. While aspirin is effective, newer drugs targeting platelet receptors and thrombin show promise for better antithrombotic therapy.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Thrombotic vascular occlusion, leading to myocardial infarction, involves platelet stimulation, coagulation cascade activation, and endothelial dysfunction.
- Platelets are activated by multiple mediators, suggesting redundancy that could limit the efficacy of single-target antiplatelet drugs.
- Aspirin's success may stem from its inhibition of thromboxane A2 (TxA2), a crucial amplification signal for platelet agonists.
Purpose of the Study:
- To review the mechanisms of thrombotic vascular occlusion and the role of antiplatelet and anticoagulant therapies.
- To evaluate the efficacy and safety of existing and novel antithrombotic agents.
- To discuss the potential of new antiplatelet and direct thrombin inhibitor drugs in managing thrombotic vascular disease.
Main Methods:
- Review of existing literature on platelet activation, coagulation, and antithrombotic drug mechanisms.
- Analysis of clinical trial data and preclinical findings for various antithrombotic agents.
- Comparative assessment of aspirin, heparin, warfarin, glycoprotein IIb/IIIa inhibitors, and direct thrombin inhibitors.
Main Results:
- Aspirin's efficacy is linked to its inhibition of TxA2 amplification.
- Heparin and warfarin reduce mortality in thrombotic vascular disease.
- Novel antiplatelet agents (e.g., targeting glycoprotein IIb/IIIa) and direct thrombin inhibitors show greater potency in preclinical models than aspirin and heparin, respectively.
Conclusions:
- Redundancy in platelet activation pathways necessitates exploring comprehensive antithrombotic strategies.
- Newer agents targeting glycoprotein IIb/IIIa and direct thrombin inhibitors offer theoretical advantages over current therapies.
- Further clinical evaluation is crucial to determine the safety and efficacy of these advanced antithrombotic drugs in humans.
Abstract:
The stimulation of platelets, activation of the coagulation cascade, release of platelet-derived vasoconstrictors, and endothelial dysfunction all contribute to the thrombotic vascular occlusion that results in myocardial infarction. Despite the importance of platelets in the initiation of this process, they are activated by multiple endogenous mediators. Thus, one might anticipate that redundancy in the system would confound the efficacy of antiplatelet drugs that were mediator-specific. The success of aspirin in clinical trials is likely to reflect the role of thromboxane A2 (TxA2) as an amplification signal for other platelet agonists. Activated platelets provide a substrate for assembly of the prothrombinase complex and both heparin and warfarin also reduce the mortality due to thrombotic vascular disease. The relative efficacy of these compounds versus aspirin and the safety of their combination, particularly in the setting of therapeutic thrombolysis, are under investigation. Novel antiplatelet agents, particularly those directed against the glycoprotein 11b/111a complex, are more potent than aspirin in animal models. Similarly, direct thrombin inhibitors seem superior to heparin. Whether such compounds can be administered safely in effective doses to humans is under study. It is hoped that the success of aspirin does not impede the clinical evaluation of theoretically more attractive antithrombotic drugs.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:27Coronary Artery Disease V: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care